🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

908 Devices Inc. MASS R2K

Healthcare · Medical Devices · United States
https://908devices.com

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

READ MORE ›
$8.41
+48.06% 1Y

Market & Price

Market Cap
$318.01M
Current Price
$8.41
High / Low (52W)
$9.15 / $5.09
Beta
0.56

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$3.96
Price to Book
2.13
P/S
5.50
EV/EBITDA
-11.16
Dividend Yield
-

Profitability & Returns

ROCE
-16.46%
ROE
-24.11%
ROA
-7.58%
Profit Margin
-62.40%
Op Margin
-48.60%
EPS (Latest Qtr)
$-0.32
EPS (TTM)
$-0.97

Balance Sheet & Liquidity

Debt/Equity
3.33
Quick Ratio
3.07
Current Ratio
3.58
Debt
$4.47M
Total Assets
$190.07M
Current Assets
$144.56M
Working Capital
$110.50M

Ownership

Promoter Holding
8.97%
Chg in Prom Hold
-
FII / Inst Holding
90.63%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$210.74M
Total Revenue (TTM)
$57.80M
EBITDA
$-18.88M
Free Cash Flow
$13.74M
Operating Cash Flow
$-7.46M
Shares Outstanding
37.81M
Gross Margin
52.01%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
6.25%
Profit 5Y
52.69%
Revenue (YoY)
13.60%
Earnings (YoY)
-

PROS

  • Profit CAGR of 52.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MASS 908 Devices Inc. R2K 8.41 - $318.01M - -16.46% -24.11% 6.25% 52.69%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4.00M11.13M6.05M5.54M8.28M12.54M8.31M11.11M15.80M9.49M12.09M14.30M7.42M11.46M--11.78M13.04M14.01M17.38M13.38M
Cost of Revenue ----------------6.24M6.66M6.65M8.23M6.50M
Gross Profit 2.10M6.41M3.84M2.91M4.38M6.81M4.13M6.63M9.34M4.38M5.79M7.87M3.89M6.16M--5.54M6.37M7.36M9.15M6.88M
Operating Expenses ----------------14.07M14.74M12.97M12.32M13.38M
Operating Income -2.76M2.13M-1.29M-5.81M-7.46M-5.28M-9.52M-8.37M-7.15M-13.02M-10.94M-9.09M-7.61M-8.54M---8.53M-8.37M-5.62M-3.17M-6.50M
EBITDA -----------------7.24M-7.40M-4.53M-2.06M-5.36M
Interest Expense --------------00-----
Pretax Income -----------------9.84M-12.84M-14.88M4.21M-11.96M
Tax Provision --------------0-71.00K-71.00K29.00K-166.00K-
Net Income -2.97M2.10M-1.72M-6.09M-7.42M-5.18M-9.41M-8.10M-6.26M-12.53M-9.35M-7.09M-10.92M-12.55M--43.60M-13.31M-14.98M4.17M-11.96M
Diluted EPS -0.600.10-0.34-0.22-0.27-0.19-0.30-0.26-0.20-0.39-0.29-0.22-0.33-0.37--1.23-0.37-0.410.10-0.32
R&D Expense 2.16M1.85M1.95M2.96M3.06M3.30M3.90M4.29M4.67M5.40M5.53M5.54M3.29M3.59M4.21M-3.83M4.41M3.84M-3.47M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 26.89M-46.85M50.23M47.75M56.20M
Cost of Revenue --20.83M24.91M23.25M27.77M
Gross Profit 14.92M-26.02M25.32M24.50M28.42M
Operating Expenses --61.41M67.97M54.45M54.10M
Operating Income -5.82M--35.38M-42.65M-29.95M-25.68M
EBITDA ---31.82M-34.02M-25.27M-21.21M
Interest Expense -486.00K129.00K201.00K0-
Pretax Income ---33.56M-36.61M-53.14M-33.34M
Tax Provision --0-211.00K0-66.00K
Net Income -12.82M--33.56M-36.40M-72.21M19.49M
Diluted EPS -2.35-0.79-1.07-1.13-2.12-
R&D Expense 8.23M13.07M17.53M21.90M14.99M15.57M

Compounded Sales Growth

5 Years:6.25%
1 Year:13.60%

Compounded Profit Growth

5 Years:52.69%
1 Year:-

Stock Price Performance

1 Year:+48.06%
6 Months:+30.19%
3 Months:+21.88%
1 Month:+29.38%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -178.83M-242.59M202.98M159.48M190.07M
Current Assets ---215.63M173.79M103.06M144.56M
Cash & Equivalents -159.23M-188.42M121.04M43.35M70.52M
Inventory ---12.51M14.94M10.89M12.99M
Receivables ---10.03M8.99M8.85M11.33M
Total Liabilities -39.79M-51.99M37.49M44.88M46.37M
Current Liabilities -10.83M-19.23M22.55M25.15M34.06M
Long Term Debt -14.33M15.00M15.00M---
Total Debt ---19.51M5.95M4.07M4.63M
Total Equity -63.17M139.04M-190.60M165.49M114.59M143.70M
Shares Outstanding ---31.86M32.52M35.10M36.32M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 4.13M--20.93M-25.06M-30.25M-23.69M
Investing Cash Flow -9.00K--15.81M-26.40M-46.32M50.75M
Financing Cash Flow 137.19M-1.18M-15.94M-376.00K-697.00K
Capital Expenditure -9.00K--2.04M-2.04M-602.00K-955.00K
Free Cash Flow 4.12M--22.98M-27.10M-30.85M-24.64M
Net Change in Cash ---35.56M-67.39M-76.94M26.36M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 55.5%-55.5%50.4%51.3%50.6%
Operating Margin % -21.6%--75.5%-84.9%-62.7%-45.7%
Net Margin % -47.7%--71.6%-72.5%-151.2%34.7%
ROE % -9.2%--17.6%-22.0%-63.0%13.6%
ROCE % -3.5%--15.8%-23.6%-22.3%-16.5%

Shareholding Pattern

Insiders
8.97%
Institutions
90.63%
Public Float
99.55%

Top Institutional Holders

#Holder% HeldSharesValue
1 First Light Asset Management, LLC 16.06% 6.07M $51.07M
2 AWM Investment Company, Inc. 13.75% 5.20M $43.73M
3 ARK Investment Management, LLC 5.15% 1.95M $16.37M
4 Blackrock Inc. 4.67% 1.77M $14.86M
5 Needham Investment Management, L.L.C. 3.28% 1.24M $10.43M
6 Vanguard Capital Management LLC 2.96% 1.12M $9.41M
7 First Eagle Investment Management, LLC 2.13% 803.61K $6.76M
8 Geode Capital Management, LLC 1.84% 695.46K $5.85M
9 Granahan Investment Management LLC 1.84% 695.07K $5.85M
10 State Street Corporation 1.66% 625.89K $5.26M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MASS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space